TrialJournal of neuro-oncology2026

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

Karan S Dixit et al.PubMed ↗Publisher ↗

No numbers read from the abstract.